fondaparinux 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
synthetic heparinoids 1236 104993-28-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fondaparinux
  • fondaparin
  • heparin pentasaccharide
  • fondaparinux sodium
  • arixtra
  • fondaparin sodium
Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.
  • Molecular weight: 1508.22
  • Formula: C31H53N3O49S8
  • CLOGP: -10.96
  • LIPINSKI: 3
  • HAC: 52
  • HDO: 19
  • TPSA: 805.48
  • ALOGS: -2.28
  • ROTB: 27

Drug dosage:

DoseUnitRoute
2.50 mg P

ADMET properties:

PropertyValueReference
CL (Clearance) 0.07 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.21 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 19.30 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 20 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
Vd (Volume of distribution) 0.14 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 7, 2001 FDA MYLAN IRELAND LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 699.34 18.94 238 10855 38810 90578544
Muscle haemorrhage 379.95 18.94 87 11006 3259 90614095
Pulmonary embolism 314.94 18.94 197 10896 130623 90486731
Anaemia 255.72 18.94 262 10831 352540 90264814
Heparin-induced thrombocytopenia 203.27 18.94 58 11035 5254 90612100
Shock haemorrhagic 193.11 18.94 68 11025 12177 90605177
Cerebral haemorrhage 189.84 18.94 90 11003 34432 90582922
Deep vein thrombosis 164.39 18.94 115 10978 91505 90525849
Haemorrhage 155.49 18.94 100 10993 69269 90548085
Haemoglobin decreased 152.18 18.94 139 10954 161817 90455537
Incorrect product administration duration 149.62 18.94 64 11029 19258 90598096
Intra-abdominal haematoma 141.49 18.94 36 11057 2108 90615246
Melaena 136.05 18.94 72 11021 34725 90582629
Post procedural haemorrhage 135.44 18.94 48 11045 8750 90608604
Post procedural haematoma 125.77 18.94 30 11063 1342 90616012
Retroperitoneal haematoma 107.72 18.94 32 11061 3336 90614018
Subcutaneous haematoma 106.66 18.94 28 11065 1855 90615499
Subdural haematoma 99.51 18.94 46 11047 16599 90600755
Thrombocytopenia 94.71 18.94 122 10971 208603 90408751
Abdominal wall haematoma 90.69 18.94 28 11065 3324 90614030
Hypersensitivity myocarditis 88.20 18.94 17 11076 269 90617085
Haematemesis 86.52 18.94 53 11040 33673 90583681
Thrombosis 80.94 18.94 69 11024 73182 90544172
Incision site haematoma 78.13 18.94 13 11080 83 90617271
Compartment syndrome 77.41 18.94 24 11069 2888 90614466
Haemorrhage subcutaneous 73.78 18.94 24 11069 3372 90613982
Blood loss anaemia 73.27 18.94 32 11061 10108 90607246
Sinobronchitis 67.75 18.94 16 11077 685 90616669
Gastrointestinal haemorrhage 59.61 18.94 64 11029 90184 90527170
Tooth erosion 56.55 18.94 13 11080 494 90616860
Extradural haematoma 54.79 18.94 17 11076 2051 90615303
Hypovolaemic shock 53.25 18.94 23 11070 7071 90610283
Intra-abdominal haemorrhage 50.57 18.94 17 11076 2645 90614709
Allergic sinusitis 50.27 18.94 16 11077 2097 90615257
Incision site haemorrhage 48.88 18.94 12 11081 606 90616748
Fatigue 48.76 18.94 42 11051 1153981 89463373
Thrombocytosis 43.88 18.94 20 11073 6981 90610373
Toxic skin eruption 43.56 18.94 26 11067 15748 90601606
Pulpitis dental 42.73 18.94 12 11081 1024 90616330
Renal failure 40.72 18.94 64 11029 130943 90486411
Leukocytosis 40.07 18.94 32 11061 30958 90586396
Skin necrosis 39.34 18.94 25 11068 16916 90600438
Neurological decompensation 38.77 18.94 15 11078 3486 90613868
Drug interaction 38.12 18.94 96 10997 276357 90340997
Autoimmune thyroiditis 37.45 18.94 17 11076 5876 90611478
Abdominal discomfort 36.69 18.94 7 11086 477321 90140033
Cerebral haematoma 35.82 18.94 15 11078 4274 90613080
Haemoperitoneum 35.14 18.94 14 11079 3514 90613840
Injection site haematoma 34.84 18.94 17 11076 6905 90610449
Red blood cell count decreased 34.40 18.94 35 11058 46316 90571038
Wound haemorrhage 34.32 18.94 13 11080 2854 90614500
Abdominal wall haemorrhage 33.63 18.94 7 11086 166 90617188
Shock 33.60 18.94 28 11065 28750 90588604
Intraventricular haemorrhage 32.49 18.94 12 11081 2457 90614897
Weight increased 32.39 18.94 6 11087 417921 90199433
Oesophageal candidiasis 32.08 18.94 16 11077 6813 90610541
Venous thrombosis limb 31.94 18.94 13 11080 3449 90613905
Haematocrit decreased 31.79 18.94 32 11061 41800 90575554
Gastric haemorrhage 31.48 18.94 16 11077 7087 90610267
Splenic rupture 31.05 18.94 10 11083 1361 90615993
Adrenal haemorrhage 30.66 18.94 8 11085 517 90616837
Periodontitis 30.59 18.94 13 11080 3840 90613514
Retroperitoneal haemorrhage 29.91 18.94 12 11081 3068 90614286
Drug hypersensitivity 29.49 18.94 10 11083 463599 90153755
Pain 29.45 18.94 48 11045 996293 89621061
Hepatic infarction 28.54 18.94 8 11085 678 90616676
Contraindicated product administered 28.54 18.94 3 11090 320136 90297218
Joint swelling 28.49 18.94 13 11080 503287 90114067
Rectal haemorrhage 27.91 18.94 42 11051 82702 90534652
Insomnia 27.59 18.94 4 11089 333470 90283884
Headache 26.97 18.94 40 11053 862706 89754648
Rash maculo-papular 26.96 18.94 29 11064 40904 90576450
Sinusitis 26.42 18.94 5 11088 343083 90274271
Procedural haemorrhage 26.34 18.94 11 11082 3113 90614241
Hepatic function abnormal 25.70 18.94 30 11063 46258 90571096
Nasopharyngitis 25.50 18.94 9 11084 407095 90210259
Nasal polyps 25.12 18.94 16 11077 10864 90606490
Hypoperfusion 24.69 18.94 9 11084 1775 90615579
Spinal cord compression 24.53 18.94 12 11081 4899 90612455
Postoperative wound complication 24.42 18.94 8 11085 1149 90616205
Abdominal pain 24.05 18.94 104 10989 395617 90221737
Prothrombin level decreased 23.97 18.94 7 11086 687 90616667
Eosinophilia 23.86 18.94 23 11070 28510 90588844
Hemiplegia 23.74 18.94 18 11075 16142 90601212
Platelet count increased 23.74 18.94 20 11073 20839 90596515
Musculoskeletal stiffness 23.52 18.94 4 11089 296528 90320826
Haematuria 23.44 18.94 25 11068 34912 90582442
Haemoptysis 22.63 18.94 24 11069 33296 90584058
Arthralgia 22.51 18.94 38 11055 778484 89838870
Depression 21.86 18.94 5 11088 300596 90316758
Post procedural swelling 21.79 18.94 6 11087 476 90616878
Haemodynamic instability 21.63 18.94 15 11078 11724 90605630
Breast haematoma 21.19 18.94 5 11088 213 90617141
Traumatic haematoma 20.98 18.94 8 11085 1787 90615567
Ecchymosis 20.97 18.94 15 11078 12308 90605046
Gastric ulcer haemorrhage 20.77 18.94 11 11082 5300 90612054
Haematoma muscle 20.75 18.94 8 11085 1842 90615512
Bullous haemorrhagic dermatosis 20.67 18.94 5 11088 237 90617117
Nephropathy toxic 20.58 18.94 15 11078 12673 90604681
Vulvovaginal injury 20.53 18.94 6 11087 590 90616764
Spontaneous haematoma 20.44 18.94 7 11086 1151 90616203
Pallor 20.41 18.94 23 11070 34142 90583212
Pneumonitis 20.26 18.94 26 11067 44144 90573210
Brain herniation 20.20 18.94 10 11083 4190 90613164
Pelvic venous thrombosis 20.14 18.94 8 11085 1993 90615361
Small intestinal haemorrhage 19.16 18.94 8 11085 2263 90615091
Stomatitis 19.13 18.94 5 11088 274693 90342661
Epistaxis 19.08 18.94 36 11057 85089 90532265

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 263.64 19.72 119 7513 27904 42585799
Incorrect product administration duration 187.91 19.72 61 7571 5819 42607884
Heparin-induced thrombocytopenia 142.37 19.72 51 7581 6546 42607157
Muscle haemorrhage 132.61 19.72 43 7589 4082 42609621
Shock haemorrhagic 130.83 19.72 62 7570 16180 42597523
Pulmonary embolism 117.64 19.72 125 7507 119487 42494216
Cerebral haemorrhage 105.65 19.72 73 7559 38893 42574810
Anaemia 98.62 19.72 178 7454 280100 42333603
Haemorrhage 93.04 19.72 81 7551 60482 42553221
Post procedural haemorrhage 76.35 19.72 36 7596 9276 42604427
Adrenal haemorrhage 68.03 19.72 15 7617 317 42613386
Haematoma muscle 59.42 19.72 20 7612 2130 42611573
Ureteric compression 57.96 19.72 13 7619 298 42613405
Post procedural haematoma 56.56 19.72 18 7614 1607 42612096
Melaena 55.81 19.72 50 7582 38696 42575007
Subdural haematoma 52.66 19.72 39 7593 23099 42590604
Retroperitoneal haemorrhage 51.93 19.72 20 7612 3135 42610568
Tumour fistulisation 51.21 19.72 10 7622 113 42613590
Haematuria 49.04 19.72 56 7576 57743 42555960
Haemoglobin decreased 47.45 19.72 85 7547 132386 42481317
Gastroduodenal ulcer 47.20 19.72 13 7619 702 42613001
Abdominal wall haematoma 46.52 19.72 17 7615 2305 42611398
Thrombocytopenia 46.45 19.72 104 7528 190175 42423528
Deep vein thrombosis 43.67 19.72 61 7571 76896 42536807
Haematemesis 43.54 19.72 39 7593 30160 42583543
Retroperitoneal haematoma 42.01 19.72 17 7615 3034 42610669
Thrombocytosis 40.80 19.72 19 7613 4756 42608947
Extradural haematoma 39.05 19.72 13 7619 1338 42612365
Pyelocaliectasis 38.51 19.72 13 7619 1396 42612307
Intra-abdominal haematoma 37.04 19.72 13 7619 1568 42612135
Tumour perforation 36.88 19.72 10 7622 509 42613194
Device related bacteraemia 34.23 19.72 10 7622 669 42613034
Gastrointestinal haemorrhage 34.06 19.72 62 7570 97664 42516039
Thrombosis 34.03 19.72 51 7581 68460 42545243
Spinal cord haemorrhage 31.35 19.72 8 7624 321 42613382
Toxicity to various agents 30.28 19.72 3 7629 229133 42384570
Bullous haemorrhagic dermatosis 28.73 19.72 6 7626 97 42613606
Primary adrenal insufficiency 26.79 19.72 7 7625 309 42613394
Haemorrhage intracranial 26.36 19.72 23 7609 17169 42596534
Venous thrombosis 25.30 19.72 13 7619 4022 42609681
Haemorrhagic stroke 25.19 19.72 16 7616 7386 42606317
Pericardial mass 24.97 19.72 4 7628 12 42613691
Spontaneous haematoma 24.75 19.72 8 7624 750 42612953
Cerebral haematoma 23.90 19.72 14 7618 5596 42608107
Lumbosacral plexus injury 23.88 19.72 4 7628 17 42613686
Upper gastrointestinal haemorrhage 23.41 19.72 28 7604 30271 42583432
Altered state of consciousness 22.54 19.72 27 7605 29232 42584471
Autoimmune heparin-induced thrombocytopenia 20.50 19.72 4 7628 45 42613658
Gastric haemorrhage 20.13 19.72 16 7616 10499 42603204
Intra-abdominal haemorrhage 20.01 19.72 10 7622 2918 42610785
Haemarthrosis 19.78 19.72 11 7621 3987 42609716

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 733.37 18.87 280 14447 58196 110516376
Pulmonary embolism 344.64 18.87 260 14467 214214 110360358
Heparin-induced thrombocytopenia 316.22 18.87 99 14628 11325 110563247
Muscle haemorrhage 315.02 18.87 88 14639 6781 110567791
Cerebral haemorrhage 264.58 18.87 142 14585 64826 110509746
Shock haemorrhagic 255.70 18.87 106 14621 27141 110547431
Anaemia 251.31 18.87 335 14392 546751 110027821
Incorrect product administration duration 193.16 18.87 80 14647 20418 110554154
Haemorrhage 183.65 18.87 135 14592 106557 110468015
Deep vein thrombosis 167.61 18.87 143 14584 139744 110434828
Post procedural haemorrhage 137.60 18.87 58 14669 15454 110559118
Melaena 134.31 18.87 94 14633 68663 110505909
Post procedural haematoma 126.43 18.87 35 14692 2604 110571968
Haemoglobin decreased 113.20 18.87 152 14575 248575 110325997
Intra-abdominal haematoma 112.63 18.87 34 14693 3438 110571134
Haematemesis 111.24 18.87 79 14648 59029 110515543
Thrombocytopenia 108.14 18.87 178 14549 348707 110225865
Abdominal wall haematoma 103.70 18.87 36 14691 5669 110568903
Subdural haematoma 98.35 18.87 61 14666 36393 110538179
Adrenal haemorrhage 95.06 18.87 22 14705 790 110573782
Retroperitoneal haematoma 93.65 18.87 34 14693 6097 110568475
Thrombosis 92.85 18.87 92 14635 108570 110466002
Hypersensitivity myocarditis 83.20 18.87 17 14710 336 110574236
Subcutaneous haematoma 82.68 18.87 26 14701 3010 110571562
Extradural haematoma 75.98 18.87 25 14702 3344 110571228
Haematoma muscle 75.08 18.87 26 14701 4064 110570508
Sinobronchitis 72.37 18.87 16 14711 466 110574106
Haematuria 72.23 18.87 71 14656 82934 110491638
Blood loss anaemia 72.18 18.87 39 14688 17986 110556586
Thrombocytosis 63.56 18.87 30 14697 10414 110564158
Ureteric compression 61.66 18.87 13 14714 301 110574271
Drug interaction 61.05 18.87 175 14552 500008 110074564
Gastrointestinal haemorrhage 60.23 18.87 91 14636 165427 110409145
Retroperitoneal haemorrhage 58.23 18.87 24 14703 6041 110568531
Incision site haemorrhage 54.61 18.87 15 14712 1083 110573489
Pyelocaliectasis 54.33 18.87 15 14712 1104 110573468
Tumour fistulisation 52.45 18.87 10 14717 136 110574436
Tooth erosion 52.04 18.87 12 14715 424 110574148
Allergic sinusitis 51.63 18.87 16 14711 1765 110572807
Hypovolaemic shock 51.37 18.87 29 14698 14554 110560018
Compartment syndrome 48.77 18.87 21 14706 5889 110568683
Bullous haemorrhagic dermatosis 48.63 18.87 11 14716 356 110574216
Gastroduodenal ulcer 47.07 18.87 13 14714 958 110573614
Skin necrosis 45.72 18.87 31 14696 21481 110553091
Haemorrhage subcutaneous 43.48 18.87 19 14708 5520 110569052
Injection site haematoma 41.53 18.87 18 14709 5128 110569444
Gastric haemorrhage 41.32 18.87 26 14701 15889 110558683
Brain herniation 40.65 18.87 21 14706 8842 110565730
Wound haemorrhage 39.63 18.87 17 14710 4721 110569851
Weight increased 38.90 18.87 5 14722 419639 110154933
Toxic skin eruption 38.89 18.87 31 14696 27484 110547088
Nasopharyngitis 38.30 18.87 4 14723 394357 110180215
Spinal cord haemorrhage 38.25 18.87 10 14717 598 110573974
Spontaneous haematoma 38.07 18.87 13 14714 1948 110572624
Tumour perforation 37.66 18.87 10 14717 635 110573937
Haemorrhage intracranial 37.48 18.87 31 14696 28938 110545634
Pulpitis dental 36.97 18.87 12 14715 1537 110573035
Fatigue 35.23 18.87 68 14659 1215890 109358682
Autoimmune thyroiditis 34.66 18.87 17 14710 6417 110568155
Neurological decompensation 33.57 18.87 17 14710 6866 110567706
Upper gastrointestinal haemorrhage 33.09 18.87 37 14690 50059 110524513
Acute coronary syndrome 32.58 18.87 26 14701 23086 110551486
Incision site haematoma 32.42 18.87 7 14720 182 110574390
Altered state of consciousness 32.11 18.87 39 14688 57587 110516985
Toxicity to various agents 32 18.87 12 14715 480543 110094029
Eosinophilia 31.94 18.87 39 14688 57897 110516675
Rash maculo-papular 31.63 18.87 44 14683 74178 110500394
Haemoperitoneum 31.33 18.87 15 14712 5373 110569199
Device related bacteraemia 31.28 18.87 10 14717 1220 110573352
Drug hypersensitivity 30.81 18.87 11 14716 454079 110120493
Haemothorax 30.36 18.87 16 14711 7015 110567557
Pain 29.77 18.87 51 14676 954904 109619668
Coma 29.71 18.87 55 14672 117814 110456758
Abdominal discomfort 29.47 18.87 8 14719 393850 110180722
Haemorrhagic stroke 27.24 18.87 19 14708 13770 110560802
Autoimmune heparin-induced thrombocytopenia 26.73 18.87 5 14722 61 110574511
Joint swelling 26.39 18.87 13 14714 442832 110131740
Insomnia 25.74 18.87 8 14719 360582 110213990
Venous thrombosis limb 25.67 18.87 13 14714 5252 110569320
Rectal haemorrhage 25.43 18.87 52 14675 119781 110454791
Oesophageal candidiasis 25.41 18.87 17 14710 11517 110563055
Lumbosacral plexus injury 25.07 18.87 4 14723 17 110574555
Hepatic infarction 25.05 18.87 8 14719 973 110573599
Venous thrombosis 24.89 18.87 15 14712 8490 110566082
Primary adrenal insufficiency 24.12 18.87 7 14720 617 110573955
Pericardial mass 23.78 18.87 4 14723 25 110574547
Renal failure 23.53 18.87 75 14652 226499 110348073
Ecchymosis 23.36 18.87 19 14708 17319 110557253
Arterial haemorrhage 23.33 18.87 11 14716 3808 110570764
Leukocytosis 23.06 18.87 32 14695 53796 110520776
Infusion related reaction 22.99 18.87 11 14716 381151 110193421
Periodontitis 22.91 18.87 12 14715 5196 110569376
Haemodynamic instability 22.59 18.87 21 14706 22867 110551705
Procedural haemorrhage 22.44 18.87 12 14715 5415 110569157
Therapeutic product effect decreased 22.41 18.87 3 14724 244313 110330259
Cross sensitivity reaction 22.16 18.87 12 14715 5555 110569017
Shock 21.69 18.87 31 14696 53557 110521015
Haemarthrosis 21.64 18.87 13 14714 7316 110567256
Mobility decreased 21.58 18.87 3 14724 237419 110337153
Wheezing 21.46 18.87 4 14723 255226 110319346
Abdominal pain 21.45 18.87 129 14598 512860 110061712
Spinal cord compression 21.28 18.87 13 14714 7539 110567033
Nasal polyps 21.10 18.87 16 14711 13184 110561388
Postoperative wound complication 21.05 18.87 8 14719 1628 110572944
Cerebral haematoma 20.75 18.87 14 14713 9618 110564954
Electrocardiogram QT prolonged 20.47 18.87 45 14682 108915 110465657
Musculoskeletal stiffness 20.34 18.87 6 14721 279816 110294756
Brain stem haemorrhage 20.19 18.87 8 14719 1818 110572754
Gastric ulcer haemorrhage 20.16 18.87 14 14713 10080 110564492
Pericardial haemorrhage 20.08 18.87 11 14716 5206 110569366
Product dose omission issue 19.85 18.87 9 14718 321773 110252799
Intra-abdominal haemorrhage 19.84 18.87 11 14716 5331 110569241
Cerebellar haematoma 19.67 18.87 6 14721 628 110573944
Intraventricular haemorrhage 19.53 18.87 11 14716 5496 110569076
Depression 19.38 18.87 9 14718 317326 110257246
Hypoperfusion 18.93 18.87 9 14718 3172 110571400

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AX05 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Other antithrombotic agents
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
MeSH PA D065427 Factor Xa Inhibitors
FDA MoA N0000175635 Factor Xa Inhibitors
FDA EPC N0000175637 Factor Xa Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:74518 anti-obesity agent

Related Drugs by ATC class:

B01AX Other antithrombotic agents 3 drugs
caplacizumabdefibrotidedermatan sulfate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Deep venous thrombosis indication 128053003
Pulmonary thromboembolism indication 233935004
Prevention of deep vein thrombosis indication 439993001
Myocardial infarction off-label use 22298006 DOID:5844
Acute coronary syndrome off-label use 394659003
Diabetic retinopathy contraindication 4855003 DOID:8947
Gastrointestinal ulcer contraindication 40845000
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Operation on brain contraindication 70586009
Heparin-induced thrombocytopenia contraindication 73397007
Kidney disease contraindication 90708001 DOID:557
Autoimmune thrombocytopenia contraindication 128091003
Hemorrhagic cerebral infarction contraindication 230706003
Local anesthetic intrathecal block contraindication 231249005
Procedure on spine contraindication 238181003
Anemia contraindication 271737000 DOID:2355
Lumbar puncture contraindication 277762005
Bacterial endocarditis contraindication 301183007
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure on eye proper contraindication 373353005
Hypertensive urgency contraindication 443482000
Significant Bleeding contraindication
Platelet Aggregation Inhibition contraindication
Placement of Epidural Catheter contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.23 acidic
pKa2 0.94 acidic
pKa3 2.46 acidic
pKa4 3.08 acidic
pKa5 11.49 acidic
pKa6 11.98 acidic
pKa7 12.26 acidic
pKa8 12.43 acidic
pKa9 12.91 acidic
pKa10 13.69 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Antithrombin-III Secreted ACTIVATOR Kd 7.49 IUPHAR CHEMBL
Coagulation factor X Enzyme IC50 7 CHEMBL

External reference:

IDSource
4021296 VUID
N0000148733 NUI
D01844 KEGG_DRUG
114870-03-0 SECONDARY_CAS_RN
4021296 VANDF
C1098510 UMLSCUI
NTO PDB_CHEM_ID
CHEMBL1201202 ChEMBL_ID
CHEMBL1200644 ChEMBL_ID
D000077425 MESH_DESCRIPTOR_UI
DB00569 DRUGBANK_ID
C049714 MESH_SUPPLEMENTAL_RECORD_UI
6819 IUPHAR_LIGAND_ID
J177FOW5JL UNII
5282448 PUBCHEM_CID
321208 RXNORM
16268 MMSL
184641 MMSL
18938 MMSL
42652 MMSL
d04786 MMSL
009549 NDDF
009550 NDDF
385517000 SNOMEDCT_US
395236007 SNOMEDCT_US
708189008 SNOMEDCT_US
CHEBI:61033 CHEBI
7653 INN_ID
J177FOW5JL INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3443 INJECTION 2.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3454 INJECTION 5 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3465 INJECTION 7.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3476 INJECTION 10 mg SUBCUTANEOUS ANDA 27 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-154 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-155 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-156 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-157 INJECTION, SOLUTION 10 mg SUBCUTANEOUS ANDA 28 sections
ARIXTRA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5501 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 27 sections
ARIXTRA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5652 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-678 INJECTION 2.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-679 INJECTION 5 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-680 INJECTION 7.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-681 INJECTION 10 mg SUBCUTANEOUS ANDA 27 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-230 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-231 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-232 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-233 INJECTION, SOLUTION 10 mg SUBCUTANEOUS ANDA 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-582 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-583 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-584 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-585 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA authorized generic 28 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-592 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 32 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-593 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 32 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-594 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 32 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-595 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA 32 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 70710-1514 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 70710-1514 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 70710-1515 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 70710-1515 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections